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The Lythraceae plant family consists of 25 genera with 
approximately 580 species including Heimia salicifolia 
(H. B. K.) Link, Heimia myrtifolia, Cham. & Schl., and 
Decodon verticillatus, L. The first crystalline lythraceae 
alkaloids were described by 'Ferris ( 1), who isola ted deca-
line, vertaline, decinine, decamine, decodine, verticilla-
tine, and vertine from samples of Decodon verticillatus 
(Table I). Commonly called "water oleander" or "$wamp 
loose-strife," this plant is found in moderate amounts 
along the Eastern seaboard of the United States and in swampy 
areas near Tallahassee, Florida. Blomster, et al. (2) re-
ported the isolation of five alkaloids from Heimia salicifolia 
(lythrine, cryogenine, sinicuichine, heimine and sinine) 
and noted the presence of a phenolic group, two methoxy 
groups, a lactone function and aromatic unsaturation for 
each of these compounds (Table I). Douglas, et al. (3) com-
pared the alkaloidal content of Heimia salicifolia and 
Heimia myrtifolia, showing that the two species have only 
1 
"l1diH1II' 1 
Table I. Alkaloids Isolated from Various Lythraceae Species 
Alkaloid Botanical Source Chemical Formula 
Lythrine Heimia salicifolia c 26H29N05 
Cryogenine Heimia salicifolia c 26H29N05 
Heimine Heimia salicifo1ia c 26H29No6 
Nesodine Heimia salicifolia c 26H29N05 
Lyfoline Heimia salicifolia c 26H29No5 
Sinicuichine Heimia salicifolia c 26H29No5 
Sinine 
(Lythridine) Heimia salicifolia c 26H31No6 
Decaline Decodon verticillatus c 26H31No5 
Vertaline Decodon verticillatus c 26H31No5 
Decinine Decodon verticillatus c 26H31No5 
Decamine Decodon verticillatus c 26H31N05 
Vertine 
(Cryogenine) Decodon verticillatus c 26H29N05 
Decodine Decodon verticillatus C25Hl9N05 
Verticillatine Decodon verticillatus C25H27N05 













































slight variations in their alkaloidal composition. These 
authors further noted the exceedingly close botanical re-
lationship between Heimia and Decodon; however, it was 
Blomster, et al. (2) who first published the empirical 
formula for cryogenine and noted its similarity to the 
Decodon alkaloid, vertine. Zacharias, et al. (4) determined 
cryogenine and vertine to be identical and established the 
structure of lythrine. The Heimia alkaloids, nesodine and 
lyfoline, have been fully characterized by Appel, et al. 
(5). 
Heimia salicifolia (H.B.K.) Link is a small shrub which 
grows in the moist highlands of Mexico and northern South 
America and is used by the natives of these regions as a 
multipurpose medicinal and hallucinogen. Known as "herva 
de la vida" (herb of life), "abre-o-sol" (sun opener) and 
"sinicuiche" (twisted foot), the plant has a folklore reputa-
tion often bordering on the supernatural. The ingestion 
of a fermented decoction of the wilted leaves is reputed to 
induce a mild euphoria consisting of visual, auditory and 
perceptual distortions and a state of deja vu whereby the 
partaker is able to remember with vivid clarity prenatal 
incidents (6). This fermented beverage is known in Mexico 
as "sinicuichi;" however, two other intoxicating plants, 
Rhynchosia praectoria, D.C. and Piscidia erythrina, L., also 
share this local nomenclature (7). 
;r=====---=--=-=---==-=--=----=-·-=---=-===--=--=---=---__ -c:----==-=-=--==--~-----==------_-_ -- --- -- ----------- ----------------
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PHARMACOLOGICAL INVESTIGATIONS 
The availability of pure alkaloids allowed Robichaud 
and Malone (8) to conduct the initial pharmacological investi-
gations of Heimia salicifolia. These authors found that 
cryogenine appeared to account qualitatively and quantita-
tively for the action of whole-plant extracts and they con-
----------- --------------- -- --------- ----- - - -- - - --- ------ ---- ----------------- --
eluded that cryogenine might possess "unique tranquilizing 
properties" since its action was devoid of the ataxic, 
blepharoptotic and autonomic side effects characteristically 
seen with reserpine and the phenothiazines. Additional work 
by these researchers (9) showed cryogenine to be active in 
reducing experimentally-induced anxiety in rats at doses 
which produce little or no side effects. 
In 1966, Jiu (10) of G. D. Searle & Co. confirmed the 
central depressant activity of Heimia salicifolia extracts 
and found the plant to exhibit significant anti-inflammatory 
activity in two experimental models of inflammation. Jiu's 
observation, coupled with independent work at The University 
of Connecticut, led Kaplan, et al. (11) to conduct the first 
comprehensive anti-inflammatory evaluation of cryogenine. 
These experiments showed cryogenine to be almost as potent 
as phenylbutazone in preventing the development of artifi-
cially-induced inflammatory responses in rats using both 
acute (carrageenan pedal edema} and chronic (Mycobacterium 
butyricum adjuvant) models of inflammation. Cryogenine's 
~~~========~-=~-=====-=--==------ :-_--_--.==----=-= -- -- ---------------------------------- ------------
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anti-inflammatory activity appeared unrelated to any toxic 
phenomena, and histopathological evaluations in rats after 
two weeks of daily oral dosing (100 mgfkg) revealed no 
lesions in any of the organs examined. 
Cryogenine antagonizes several autacoids in vitro; how-
ever, this action generally appears nonspecific and can vary 
Kinetic studies show cryogenine to be a non-competitive 
antagonist of acetylcholine (8, 9), and extremely high con-
centrations are required to block nervous transmission (9). 
While cryogenine is capable of reducing the pressor effects 
of exogenously-administered epinephrine in the anesthetized 
dog, its inability to antagonize epinephrine in the isolated 
rat vas deferens strongly supports the drug's lack of involve-
ment with adrenergic receptors (12). Trottier and Malone 
(13) found cryogenine to competitively antagonize histamine 
in the isolated guinea pig uterus; however, this antagonism 
becomes non-competitive when the drug concentration is in-
creased or when the isolated terminal ileum is used. A 
similar, non-competitive antagonism of serotonin was observed 
in the isolated rat uterus, and this finding correlates with 
cryogenine's ability to significantly reduce serotonin-
induced pedal edema in the rat (11). Cryogenine also dis-
plays a mixed antagonism against synthetic bradykinnin (14). 
However, it is doubtful that its anti-inflammatory activity 
can be wholly attributed to its ability to non-specifically 
----------------------- ---- ------------------------------------- --- -- --- -- ----------------
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antagonize autacoids at the local level and, based on its 
documented neuroleptic activity (8, 15), cryogenine's anti-
inflammatory activity may have a centrally-mediated com-
ponent. 
The ability of certain centrally-acting drugs to possess 
anti-inflammatory activity is well established and related 
_____ .to _!!l~j.r_abilj. ty_0_ji)_ :i..l!hj__1Jj_t_l11ono~mi_ne .. !'e-uR_ta~e a,nd . __ ··-·--· __ 
metabolism, (ii) alter peripheral hemodynamics, (iii) inter-
fere with ganglionic transmission, or (iv) affect the ' 
pituitary-adrenal axis. 
Structural and pharmacological similarities between 
cryogenine and tetrabenazine led Chang and Malone (16) to 
conclude that cryogenine does have a centrally-mediated 
anti-inflammatory component; neither of these two compounds 
affect liver glutathione stores nor alter peripheral cate-
cholamine levels. While cryogenine does lower mean resting 
blood pressure and induce bradycardia in anesthetized dogs 
(12), these activities cannot explain its effect against 
chronic inflammation since it is well established that such 
hemodynamic alterations can play only a minimal role. Cryo-
genine neither fa6ilitates nor inhibits ganglionic trans-
mission (8, 17). 
Cryogenine does affect the pituitary-adrenal axis but 
the nature of this involvement remains to be elucidated. 
The lack of thymic, adrenal, hepatic and hematic alterations 
in rats given oral doses (100 mgjkgjday) for 21 days first led 
7 
De Cato, et al. (18) to conclude that cryogenine's anti-
inflammatory activity is probably not mediated by the endo-
genous release of corticosteroids; however, subsequent studies 
by these investigators (19) showed that crogenine's capacity 
to suppress both granuloma weight and carrageenan-induced pedal 
edema significantly diminished in bilaterally adrenalec-
tomized rats. Therefore, cryogenine's anti-inflammatory 
activity may be due, in part, to the release of some adrenal 
principle. This hypothesis is supported by cryogenine's 
limited effectiveness in suppressing ultraviolet-induced 
erythema in guinea pigs (20), an experimental model of 
inflammation that is nonresponsive to corticosteroids and 
immunosuppressants. 
Cryogenine's immunosuppressive activity was first 
evaluated by Kosersky, et al. (21) who, impressed by the 
drug's ability to inhibit both the irritant- and immune-
me~iated phases of adjuvant-induced polyarthritis (11), 
quantitatively confirmed this activity and clearly differ-
entiated the action of cryogenine from that displayed by 
6-mercaptopurine. A definitive study by Watson and Malone 
(22) confirmed cryogenine's lack of immunosuppressive 
capacfty at effective anti-inflammatory dose levels. 
The "water diuretic" property of certain lythraceae 
alkaloids was first reported by Weisbach (23) and further 
explored by Weibelhaus, et al. (24), who determined that 
lythrine and decinine, lythrine's dihydrocinnamic analog, 
---------------
8 
possessed significant activity. The failure of earlier in-
vestigators to document this capacity may be due to the 
relatively low content of lythrine found in Heimia salicifolia 
(25). Watson (26) found cryogenine to be devoid of any 
significant diuretic activity in the rat. Like prednisone, 
decinine has marked anti-inflammatory activity in several 
-~~- ___ ~!_andard_assay§_ang__!'_e_§_j;Q:r-_~d __ cl:i._l1~re~is ~il! w~ter-=lo_ad~d, 
adrenalectomized rats (24). Unlike prednisone, decinine 
also blocks the anti-diuretic effects of vasopressin in both 
dogs and rats. Weibelhaus concluded: 
" ... while decinine can completely block the 
effects of ADH, it is probably not a specific 
antagonism and the compound may cause diuresis 
by acting at additional sites. Its glucocorticoid-
like activity in adrenalectomized rats suggests 
an involvement with basement membrane permeability." 
These data support glucocorticoid-like activity for certain 
of the lythraceae alkaloids and clearly demonstrate· how 
relatively minor alterations in a complex molecular struc-
ture can greatly affect relative potencies and pharmaco-
logical activity. 
CHEMICAL INVESTIGATIONS 
There are four major groups of structurally-related 
lythraceae alkaloids (Table II) and, while all groups share 
the same basic skeleton, they differ in three specific 
regions: (~) the nature of the substituents and the pat-
tern of substitution of the biphenyl ring system, (ii) the 
presence of a cinnamic or dihydrocinnamic lactone, and 
-- --- -- - -------- ------------ --------
~ ~~---- --
Table II. Structurally-Related Lythraceae Alkaloids 
11 
OCH3 
Quinolizidine R1 R2 
Alkaloids Ring Fusion 12--13 C-4' 
Lythrine trans -CH=CH- -OCH3 
Lyfoline trans -CH=CH- -OH 
Decinine trans -CH2-CH2 -OCH3 Lythridine trans -CHOH-CH2- -OCH3 
Cryogenine cis -CH=CH- -OCH3 
Dec amine cis -CH2-CH2- -OCH3 
Heimidine cis -CHOH-CH2- -OCH3 
Nesodine trans -CH=CH-:- H 
Deco dine trans -CH2-CH H 
Dehydro- trans -CH=CH- H 
decodine 
Sinicuichine cis -CH=CH- H 
Vertacillatine cis -CH=CH- H 
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(iii) the stereo-chemistry at C-10 in the quinolizidine ring. 
The lythrine and cryogenine groups have oxygen substituents 
at the 4 I. and 5 1 posit ions on the biphenyl nucleus while the 
nesodine and verticillatine groups have oxygen substituents 
at the 5 1 and a~ positions. These groups can be divided fur-
ther on the basis of their relative configurations at C-10 
with a trans ring juncture for the nesodine and lythrine 
gr,oups while the cryogenine and verticillatine groups have 
a cis ring juncture (27). Thus cryogenine and lythrine are 
configurational isomers (the same molecular formula, the 
same pattern of aromatic substitution, and the same configura-
tion at the biphenyl linkage) and differ only in configura-
tion within the quinolizidine ring system. 
Ferris, et al. (28) first hypothesized that this charac-
teristic quinolizidine ring system was derived by the conver-
sion of lysine to delta 1 -piperidine with a subsequent trans-
formation of the latter to isopelletierine, resulting in the 
formation o~ an asymetric center adjacent to the nitrogen 
atom. This pathway was firmly established by Spencer, et al. 
(29). Rother and Schwarting (30) found that both halves 
of the .biphenyl ring system were derived from phenyl-
alanine but the exact pathway by which phenylalanine enters 
the 4-phenylquinolizidine system still remains a mystery. 
Based on these reports, Rosazza, et al. (31) used a bio-
genetic approach in an attempt to synthesize dihydrofoline 
but were unsuccessful in the oxidative coupling of the two 
~~~~~~~~~~~=~~=~-======-=-=-----__ --_-c:c=--=- ----------- :__=~~-~---- -= ::_-___ ---_---_-_------~ __ :_~--- - -- -- ------------------
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phenyl rings. However, two independent groups (32, 33) were 
able to totally synthesize (+) decaline, a minor alkaloid 
of Decodon verticillatus, which differs from the previously 
mentioned alkaloids by having a biphenyl ether linkage (34). 
Other alkaloids in this group include methyldecaline, lar-
gerine, vertaline and demethylvertaline. To date, total 
_______ ay_nth_e_si3_S __ o_f_v_ert_a1ine_(_35_), ___ me_thyldecinine __ (36) _and methyl_-______ _ 
decamine (37), a biphenylquinolizidine, have been reported. 
Derivatives with a carbon skeleton of 4-phenylquinolizidine 
represent the fundamental structure of all lythraceae alka-
loids (38) and are utilized as the key components in their 
syntheses. Two such phenylquinolizidines have been isolated 
from 5-10 day old seedlings of Heimia salicifolia but their 
absence from more mature plant samples suggests that they 
serve only as biosynthetic intermediates (39). 
STATEMENT OF PROBLEM 
The molecular complexity of the lythraceae alkaloids 
suggests that several active centers may account for their 
unique pharmacological profile. To assess these potentially 
active sites, two standard models of acute inflammation 
were selected for use in this present study -- the carrageenan-
induced rat pedal edema assay and the croton oil-induced 
mouse ear edema assay. 
The inflammatory response to an injection of carrageenan, 
a sulfated polysaccharide derived from Chondrus crispus 
- - --- ------- ----------
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(Irish sea moss), was introduced by Winter,et al. (40) and 
developed by these workers into a laboratory model for use 
in the search for new anti-inflammatory agents (41, 42). 
This inflammogen gives more consistent results than other 
agents such as formalin, dextran and egg white (40) and 
potency results correlate very well with recommended clin-
The acute inflammatory reaction which results after 
the subplantar injection of carrageenan is characteristic-
ally biphasic. The first phase begins immediately upon 
injection, diminishes within one hour and accounts for 40 
percent of the total edema. The second, more accentuated 
phase begins after one hour and persists through the third 
hour. Vinegar, et al. (44) determined that while aspirin 
will significantly inhibit both phases of edema formation, 
hydrocortisone is effective in suppressing only the second 
phase of swelling. Furthermore, the maximum suppression of 
edema formation by any one agent is only 70-75 percent. 
Van Arman concludes (45): 
"It is interesting that the upper limit of 
effectiveness of steroids and nonsteroids 
is approximately the same, but the mechanisms 
are different because one can achieve 100 per-
cent inhibition by using, for example, indomethacin 
and dexamethasone together. 
The second model utilized in this study is the croton 
oil-induced mouse ear edema assay, which was originally 
developed to determine the thymolytic and antiphlogistic 
-----------
----------------------------------- ---- -------- ----
13 
activity of topically-applied corticosteroids (46). However, 
Van Arman and co-workers (47, 48) have shown that this assay 
is also sensitive to several standard nonsteroidal anti-
inflammatory agents. Furthermore, the relative potencies 
determined by this assay correlate well with established 
clinical potencies. Since the assay is rapid, reliable, and 
________ regui:r-_es only_ll!_o_d._e_s_t__aiD.Ql.l:U_t_s_o_f_ t_e_st _COll1P9tmds , _ _it _i_s _es:pe_ci_- ____ _ 
ally well suited for natural products research, where it is 
often difficult to obtain large amounts of pure principles 
for pharmacological testing. 
While the oral anti-inflammatory capacity of several of 
the lythraceae alkaloids has been well documented, their 
topical antiphlogistic capacity has not yet been evaluated. 
Moreover, the specific function or functions of the molecule 
which account for this anti-ipflammatory capacity remain 
a mystery. The present study was undertaken: (i) to assess 
the topical anti-inflammatory potential of cryogenine, 
lythrine and two selected lythraceae intermediates and (ii) 
to investigate the possible molecular components which pro-
duce this established, yet enigmatic anti-inflammatory effect. 
--- -------------------- ---------
MATERIALS AND METHODS 
Isolation of the Alkaloids. -- Four kilograms of a methanol 
extract of dried and defatted Heimia salicifolia (prepared 
by W. C. Watson) were dissolved in 10 liters of 2 N HCl and 
centrifugally filtered through three layers of filter paper 
(Filtrax, coarse grade). The solid residue was redissolved 
in another 10 liters of 2 N HCl and continually stirred for 
seven days prior to filtration in the manner described above. 
The non-alkaloidal, nonpolar principles were then removed 
by extracting aliquots of the combined acidified filtrates 
with equal volumes of diethyl ether in a glass separatory 
funnel until the ether phase was clear and tested negative 
for alkaloids. The aqueous phase was titrated to a pH of 
9.0 by 58 percent ammonium hydroxide, yielding a rust-colored 
suspension. Aliquots of this basified, aqueous fraction 
were combined with equal volumes of chloroform in a glass 
separatory funnel and extracted until exhausted of all 
alkaloids. The resulting 60 liters of chloroform extract 
were filtered by gravity through sodium sulfate to remove 
14 
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residual water, then dried in vacuo at 40°C. The resulting 
dried chloroform extract (150 g) represented an approximate 
4 percent yield from the methanol extract. 
The dried chloroform extract was reduced to a fine 
powder in a glass mortar, dissolved in a minimum amount of 




------ paper -i-n-a-Buchner-funne-1--under-suction ~- -The filtrate was - ------- ----
added in increments to a warm evaporating dish containing 
100 g of aluminum oxide (active neutral, activity I). Re-
sidual methanol was evaporated at 40°C in vacuo, leaving 
an admixture of chloroform extract and aluminum oxide at 
a ratio of-3:2. The admixture was sprinkled onto a Bio-Rad 
glass colum_n (4.5 em~ 65 em) containing 650 g of aluminum 
oxide dry packed with benzene. The chloroform extract to 
aluminum oxide column packing represented a ratio of 4:1. 
Elution was accomplished using the following sequence of 
solvents: (!) benzene, 100 ml; (ii) benzene:chloroform 
95:5, 10 liters; (iii) benzene:chloroform 50:50, 20 liters; 
and (iv) chloroform:methanol 50:50, 3 liters. 
· The first three fractions were combined and reduced 
by flash evaporation at 40°C in vacuo. The resultant green-
yellow precipitate was dissolved in a minimum amount of 
boiling ethyl acetate and filtered through Whatman #1 filter 
paper in a Buchner funnel under suction. The filtrate was 
then heated to clarity and petroleum ether was added drop-
wise until the mixture turned slightly opaque. The mixture 
--------------------------------- ------- -----------------
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was again heated to clarity, covered and placed in a dark 
desiccator at room temperature for 24 hours. The resulting 
white crystals were collected on Whatman #1 filter paper in 
a Buchner funnel under suction. The mother liquor was then 
reduced to half volume with a current of air and crystalliza-
tion ·allowed to occur as described above. This procedure 
_________ was____!'epeated_ un_!;:i._~ no fur_!!!~:r'.-~_ry-sta.ls_ :fo_r!Ile9-. _ '!'hj.n-_!_aJT~_r 
chromatographic (TLC) analysis showed these crystals to 
contain a mixture of lythrine, cryogenine and an unidentified 
yellow pigment. 
A separat~on procedure differing from the original 
method of Blomster, et al. (2) was attempted based on pre-
liminary analytical-scale experiments which gave selective 
elution of lythrine and cryogenine by decreasing the benzene 
to chloroform ratio in five percent increments. At a 70:30 
ratio of benzene to chloroform, a pure lythrine fraction 
was eluted to exhaustion. A further decrease in the benzene 
to chloroform ratio (60:40) yielded a pure cryogenine frac-
tion. Both lythrine and cryogenine fractions were monitored 
by TLC. However, these results could not be duplicated when 
attempted on a preparative scale, so the following high 
pressure liquid chromatographic separation was developed. 
Analytical samples of six Heimia alkaloids were dis-
solved ( 1. 0 mgjml) in methanol: methylene chloride ( 70:30). 
Individual retention times were determined by injecting 10 





a Rheodyne syringe-loading sample injector fitted with a 
175-microliter sample loop. The mobile phase (methanol: 
methylene chloride 70:30) was filtered through a 0.22 micron 
Millipore filter under suction and then pumped at a rate of 
2.0 mljminute by a Perkin Elmer Series 2/1 HPLC. Separa-
tion was accomplished using a Partisil SAX 10 analytical 
He_i_mia_alkalo_ids _wer_e_ det e_c ted 
with a Perkin Elmer LC-55 spectrophotometer set at 285 
nanometers and monitored with an Omni-Scribe chart recorder. 
The column was allowed to equilibrate for two hours prior 
to use and all separations were performed at room tempera-
ture (72-75°F). Retention times for the six Heimia alka-
loids are listed in Table III. 
High pressure liquid chromatographic (HPLC) separation 
of cryogenine and lythrine on a preparative scale was then 
carried out as follows. The mixed alkaloidal fraction ob-
tained by column chromatography and corresponding to "Frac-
tion I" of Blomster, et al. ( 2) was dissolved in 1. 0 ml of 
methanol:methylene chloride (70:30) and passed through a 
Sep-Pak cartridge silica filter to remove any highly polar 
and particulate principles. The cartridge was flushed with 
4.0 ml of solvent to insure complete elution of the alkaloids. 
The filtrate was reduced to dryness by flash evaporation 
at 40°C in vacuo then re-dissolved in 2.0 ml of methanol: 
methylene chloride (70:30). A 1.0 ml aliquot was injected 
utilizing a Rheodyne sample injector fitted with a 1.1-ml 
sample loop. 
"'"""''''' , I 
I 
I 
Table III. Retention Times for Six Lythraceae Alkaloids Det~rmined by HPLC 
Alkaloid a Quantity, meg Retention Time, sec. Minor Peaks, sec. 
Lythrine 10 100 40, 50 
Lythridine 10 105 40, 600 
Nesodine 10 115 40, 50 
Lyfoline 10 170 40, 115,. 600 
Sinicuichine 50 450 40, 50, 95; 125 
Cryogenine 10 605 40, 140, 220, 
aAll alkaloids used for analytical HPLC determinations were ~xtracted from 
Heimia salicifolia by A. E. Schwarting and A. Rother at The !University of 
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The mobile phase (methanol:methylene chloride 70:30) 
was pumped at a rate of 3.0 ml/minute by a Perkin Elmer 
Series 2/1 HPLC through a Whatman Partisil 10 SAX M-9 
preparative column (9.4 mm ~ 500 mm) and passed through a 
Perkin Elmer LC-55 spectrophotometer set at 250 nanometers. 
The fractions were monitored by a Houston Instrument Omni-
of 0.25 em/minute and collected in 4.0-ml fractions. At a 
sample concentration of 50 mgfml, the resolution of the 
two alkaloidal peaks was quite distinctive. Identification 
of the peaks was determined by TLC. Lythrine eluted well 
in advance of cryogenine. 
The cryogenine fractions collected from the apex of 
its elution peak were combined and flash evaporated at 
40°C in vacuo, leaving a white precipitate. To insure that 
the cryogenine was in the free-base form, this precipitate 
was dissolved in 25 ml of 10 percent acetic acid and brought 
to a pH 0f 9.0 by the drop-wise addition of 58 percent 
ammonium hydroxide. The basic aqueous solution was placed 
in a glass separatory funnel and extracted with chloroform 
until further additions of ·6hloroform tested negative for 
cryogenine by TLC. The chloroform fraction was then flash 
evaporated at 40°C in vacuo leaving a white precipitate 
which was dissolved in a minimum amount of boiling absolute 
methanol, covered and placed overnight in a dark desiccator 
at room temperature. The resulting crystals were collected 
20 
on Whatman #1 filter paper using a Buchner funnel under sue-
tion and washed three times with cold, absolute methanol. 
The crystals were dried at room temperature in vacuo over 
phosphorous pentoxide for 24 hours. This method of isola-
tion yielded cryogenine base of high purity as determined 
by melting point, two-dimensional TLC and infra-red 
'--------s-pec-t~G-P-hG-tGme-tFy----. ----'I!he----1-y-t-h-r-i-ne----fract-ion-s --were -t-rea-t-ed-- in 
the same manner with similar results. 
Carrageenan Pedal Edema in the Rat. -- Four synthetic phenyl-
quinolizidine compounds prepared by Dr. James Quick of North-
eastern University (Figure 1) were screened in rats for 
potential anti-inflammatory activity using the carrageenan 
pedal edema assay proposed by Winter, et al. (40) and modi-
fied by Van Arman, et al. (49) . Adult, heal thy, Sprague-
Dawley derived male rats (150-170 g; Simonsen Laboratories, 
Gilroy CA) were maintained in our laboratory for one week 
after receipt with free access to Purina Laboratory Chow 
and tap water. Twenty-four hours prior to experimentation, 
the animals were placed on fast (tap water ad libitum) and 
housed in individual cages with wide-mesh screen floors to 
prevent coproph.agy. Thirty minutes prior to the carrageenan 
injection, the animals were dosed in a random pattern with 
either a test drug finely suspended in 0.25 percent agar 
or the 0.25 percent agar dosing vehicle alone. Oral admin-
istration was selected to avoid any parenteral "counterirritant" 
Figure 1. Synthetic Intermediates Prepared by Dr. James 
B. Quick. 
RR-5-2 .......... Octahydro-4-(3-hydroxy-4-methoxyphenyl) 
-2H-quinolizin-2-one; m.p. = 138-140° 
[Hexane~Benzene]; light tan-white; 1 g. 
JB-1-0 .......... 4:..(2-bromo-4,5-dimethoxyphenyl) 
-octahydro-2H-quinolizin-2-one; m.p. = 
136-1380 [Hexane]; light yellow-tan; 
700 mg. 
MM-1-0 .......... Octahydro-4-(3,4-dimethoxyphenyl)-2H-
quinolizin-2-one; viscous liquid; golden 
brown; 500 mg. 
HR-1-0 .......... 3-(4-hydroxyphenyl)-propenoic acid 
octahydro-4-(3-hydroxy-4-methoxyphenyl) 
-2H-quinolizin-2-yl ester; viscous liquid; 

















effect which might modify the development of the pedal edema. 
Five minutes before carrageenan injection, the volume of 
the right hind paw was measured plethysmographically to a 
line circumscribed just above the animals's tibio-carpal 
joint. At time zero, a subplantar injection of 0.1 ml 
of 1.0 percent carrageenan in sterile 0.9 percent saline was 
______ mad~_in_th§___r_i_gllt_hindc:Raw_ut_i_lizing a_micr_omet_er syringe 
with a 27-ga:uge 3/4-inch needle. The control group received 
an equivalent amount of sterile 0.9 percent saline. Paw 
volumes were determined as previously described at +5 and 
+30 minutes and at half-hour intervals thereafter. Tests 
for significant inhibition of carrageenan-induced pedal 
edema by the test compounds were made utilizing analysis of 
vari~nce statistical techniques. 
Croton Oil Mouse Ear Edema Assay. -- The topical anti-
inflammatory activities of selected natural and synthetic 
compounds were determined using the croton oil mouse ear 
edema assay of Tonelli, et al. (46) as modified by Van Arman 
(47). Adult, healthy Swiss-Webster derived female mice 
(17-20 g; Simonsen Laboratories, Gilroy CA) were housed in 
our facilities for at least one week prior to use and given 
Purina Laboratory Chow and tap water ad libitum. One hour 
prior to experimentation, the mice were randomly placed in 
individual cages with wide-mesh screen floors to prevent 
coprophagy and provided free access to food and tap water 
24 
for the remainder of the experiment. Each mouse was anes-
thetized with ether and, upon loss of righting reflex, 0.1 
ml of a solution containing 2 percent croton oil, 73 percent 
ether, 20 percent pyridine and 5 percent double-distilled 
water was applied in four aliquots using a 25-microliter 
Eppendorf pipette (two applications to the anterior and two 
-----~-- --t-o- the-posterior -surfaces of- each animal' s·right ~-ear}.-
One hour after the application of the croton oil solu-
tion, the individual test compounds were dissolved or sus-
pended at concentrations containing the specified drug dose 
in 0.1 ml of a vehicle consisting of 75 percent ether, 20 
percent pyridine and 5 percent double-distilled water. 
The mice were again anesthetized with ether and 0.1 ml of 
drug solution/suspension applied to the right ear in the 
manner previously described. Vehicle alone was applied to 
the ears of the control animals. 
Th~ee hours after the drug applications, the mice were 
sacrificed with ether and both the right and left ears ex-
cised at the base. A 8.0-mm circle of ear tissue was re-
moved with a size #4 cork borer, using the outer margin of 
the ~ar as a landmark in order to avoid the extra hair and 
tissue found at the base of the ear. The sections were 
placed in marked spot-test plates to insure proper identifica-
tion and then individually weighed to the nearest tenth of 
a milligram on a Sartorius laboratory balance. 
The increase in weight induced by croton oil was found 
25 
by subtracting the weight of the untreated left ear section 
from that of the right ear section. Drug effects (expres-
sed as percent inhibition) were determined by subtracting the 
weight increase of treated individual ears from the mean 
weight increase of the control group and the difference times 
100 divided by the mean weight increase of the controls. 
_______ Anal~siS_Q:f _ _ya:r_ian_ce_sta_tistLcal_t_echniques __ were __ used _to 
determine the significance of any inhibition of the croton 
oil-induced ear edema. 
RESULTS 
Carrageenan-Induced Rat Pedal Edema Assay. -- The sub-
plantar injection of carrageenan resulted in the charac~ 
teristic btphasic acute inflammatory response (Table IV, 
Figure 2). Orally administered aspirin (400 mgjkg) sig-
nificantly (P < 0.05) inhibited the acute inflammatory re-
action at all time intervals evaluated (Table IV). Indo-
methacin given orally (12.5 mgjkg) displayed noticeable 
anti-inflammatory activity; however, this activity became 
significant (P < 0.05) only during the final half hour of 
the five-hour evaluation (Table IV, Figure 3). Indometha-
cin's lack of activity in suppressing the first phase of 
carrageenan-induced pedal edema is well established (44); 
however, its delayed onset during the present study may 
be due, in part, to the interval between drug dosing and 
carrageenan injection which was shortened by one-half hour 







Table IV. Effects of Seven Orally Administered Selected Drugs 




(!! = 7) 
------ ·--- ---· --whole-BodY----- --1-55-~-6+9~ 4--
Weight, g (> o-:-5o) 
Paw Volume, 
ml, -5 min. 
Paw Volume, 
ml +5 min. 
Volume Change 
From +5 min 
+30 min, ml 
+60 min, ml 
+90 min, ml 
+120 min, ml. 
.+150 min, ml 
+180 min, ml 
+210 min, ml 
0.92+0.05 
(> 0. 60) 
1. 08+0. 05 
















Mean ± 1 SEM (Significance Level ~ 
Carrageenin 
Control 
(!! = 10) 
0.89+0.02 










(!! = 10) 
---- ·- - - 159:-o+5~o-- ---
(> 0. 60) 
0.88+0.03 
(> 0. 70) 
1. 06+0. 04 
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~. Carrageenin Control, P)a 
Indomethacin, 
12.5 mg/kg 
(! = 10) 
RR-5-2, 
100 mg/kg 
(~ = 10) 
JB-1-0, 
100 mg/kg 
(N = 10) 
______ lM. 0-1--5.3_. ___ -.-164.5-!-5. 0-- --160. 4+4. 9 
(> o:-8o) (> o:-7o) (> o:-8o) 
0.94±0.03 



























































(~ = 10) 
___ 1 t=,/, ()-I..~ -~- 1 t=.O _?-l...t=. _/, __ - - --- -- -
..a..v-r•vtJeJ - -..~-vv•w•v•"""' 







1. 05+0. 04 
(> 0.50) 
+0.18+0.02 +0.17+0.04 
(> o. 90) (> o:-8o) 
+0.33+0.04 +0.31+0.06 
(> 0.90) (> 0.90) 
+0.40+0.05 +0.34+0.07 
(> 0.40) (> 0.90) 
+0.40+0.05 +0.36+0.06 
(> o-:-3o) (> o:-6o) 
+0.40+0.05 +0.38+0.06 
(> o:-7o) (> o:-8o) 
+0.47+0.07 +0.42+0.06 
(> o-:-7o) (> o-:-9o) 
+0.48+0.06 +0.47+0.07 
(> o-:-8o) (> o-:-9o) 
'1 
LL 





(.!'!_ = 7) 
- --From--1-5-min--- ------------ __________ _ 
+240 min, m1 
+270 min, ml 




c < o:ool)* 
-0.05+0.03 
(< o:ool)* 
------------ -- ----- - --- ---------------- --------------
Mean± 1 SEM (Significance Level 
Carrageenin 
Control 






(.!'!_ = 10) 
+0.13+0.05 
( < o:ol)* 
+0.12+0.05 
c < o:ol)* 
+0.10+0.04 
( < o:ool)* 
aAsterisks have been added to emphasize statistical significance. 
= 
a vs. Carrageenin Control, P) 
Indomethacin, 
12.5 mg/kg 
(N = 10) 
+0.29+0.05 
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Figure 2. Time Course of Carrageenan-Induced Pedal Edema in ~he Rat. 
I 
x ; Carrageenan Control 
a ; Aspirin (400 mgjkg) 
~ ; JB-1-0 (100 mgfkg) 
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Figure 3. Time Course of Carrageenan-Induced Pedal Edema in tlhe Rat. 
x = Carrageenan Control 
o = Indomethacin (12.5 mgfkg) 
D. = JB-1-0 (100 mg/kg) 
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JB-1-0 showed significant (P < 0.05) anti-inflammatory 
activity at times +180 through +210 minutes (Table IV, 
Figure 2) when given orally at a dose of 100 mgjkg. At 
this dose level, a marked sedation was noted in all animals 
screened. This peculiar sedation, which began two hours 
after the compound was administered and persisted throughout 
the course of the experiment, is noteworthy since all prior 
reports of the depressant and ataractic properties of 
lythraceae alkaloids were achieved only when the compounds 
were administered by intraperiton~al injection. Three ad-
ditional synthetic phenylquinolizidines, RR-5-2 (Figure 4), 
MM-1-0 (Figure 5) and HR-1-0 (Figure 6) were essentially 
devoid of any real anti-inflammatory activity when given 
orally at a dose of 100 mgjkg. --this dosage of cryogenine 
will consistently suppress the second stage inflammatory 
response of carrageenan pedal edema (11, 19, 21). 
Croton Oil-Induced Mouse Ear Edema Assay.--The topical 
application of croton oil produced a significant increase in 
ear weight characterized by edema, hyperemia and an overall 
increase in ear size. Table V and Figures 7 - 9 depict the 
dose-response data (8 mice per dose) used to calculate the 
respective potencies and ID50 (mgjear to produce the 50 per-
cent suppression of edema) values that are summarized in 
Table VI. An assay l.ambda ( sjb) could not be calculated 
for the assay of dexamethasone vs indomethacin since the 
Figure 4. Time Course of Carrageenan-Induced Pedal Edema in!the Rat. 
x = Carrageenan Control 
o = RR-5-2 (100 mgjkg) 
~ = JB-1-0 (100 mgjkg) 

















' ' ' ' X 
' \ 






























































L~ HZU~W~OOW HZ >O~~LW 
Figure 5. Time Course of Carrageenan-Induced Pedal Edema in!the Rat. 
x = Carrageenan Control 
a = MM-1-0 (100 mgjkg) 
~ = JB-1-0 (100 mgjkg) 
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Figure 6. Time Course of Carrageenan-Induced Pedal Edema inithe Rat. 
x = Carrageenan Control 
a = HR-1-0 (100 mgfkg) 
~ = JB-1-0 (100 mgjkg) 
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Table V. Drug Effects on Croton Oil-Induced Mouse Ear Edema 
Mean Valuesl (SEH) 
Drug I Percent I Percent 
Treatment (mgjear) N W -W Inflammati.on Inhibition t c I 
i 
Control 0 11 18.74 (0.84) 130.27 (5.!27) 0 
I 
I 
Indomethacin 0.5 8 12.14 (1.56) 79.50 (10).36) 36.75 (7.13) 
I 
I 
1.0 8 9.13 (1.11) 60. 00 ( 8 .. 58) 51.13 (5.98) 
I 
i 
2.0 8 5.08 (0.26) 35. 25 ( 1. :85) 73. 00 ( 1. 38) 
I 
Phenylbutazone 2.0 8 11.81 (0. 70) 79.13 (5.173) 37.13 (3.71) 
4.0 8 7.75 (1.24) 52 . 7 5 ( 8. ;36) 58.63 (6.58) 
8.0 8 6.05 (0.84) 41.38 (5.94) 67.63 (4.43) 
Aspirin 1.0 8 10.45 (1.06) 77.00 (8. 149) 44.25 (5.65) 
2.0 8 6.19 (0.81) 48.50 (6.:83) 67.00 (4.35) 
I 
4.0 8 3.08 (0.39) 22.88 (3./13) 83.63 (2.14) 
Dexamethasone 0.0001 8 10.50 (0.98) 79.13 (8.;51) 44.13 (5.29) 
0.001 8 8.04 (0.98) 64.75 (9.21) 57.38 (5.20) 
0.01 8 4.68 (0.99) 38.00 (5./84) 73.13 (4.33) ~ ~ 
I 
:::r.:r·.rllli:Jii:;nrii: :mr.L1llJUllll&r:rcm::mun::JI[tiH::.r.:.::J.: :::. r .r.:Jl::·:::mn:. -1 
,.,,, I 
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Table V. Continued 
I 
Mean Values (SEM) 
Drug Percent I Percent 
Treatment (mgjear) N w -w Inflamma tj_on Inhibition t c I 
j I 
I I 
Cryogenine 0.25 8 13.80 (2.07) 95.50 (14.!43) 31. 00 ( 8. 50) 
:J I 
i 
0.50 8 9.70 (1.23) 67.75 (8.B>7) 48.25 (6.56) 
i I i 1.0 8 6.68 (1.61) 44.88 (9.77) 64;50 (8.61) 
I 
I Lythrine 0.25 8 11.69 (1.38) 97.25 (11:.60) 37.75 (7.34) I 
i II 
0.50 8 8.46 (0.84) 69.75 (7.~n) 54.75 (4.51) II 
I 
II 1.0 8 5.61 (0.57) 49.13 (4.H3) 70.00 (3.04) 
•I 




0.50 8 6.33 (1.12) 45.13 (7.~~6) 66.38 (6.00) 
1.00 8 3.81 (0.55) 25.75 (3.97) 79.63 (2.93) 
p-Hydroxy-
cinnamic acid 1.0 8 10.73 (1.24) 93.88 (8.!35) 42.75 (6.58) 
2.0 8 7.90 (1.58) 79.63 (16!.2) 57.75 (8.46) 
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Figure 7. Log Dose-Response Curve for Six Reference Compounds lin Regard 
to the Suppression of Croton Oil-Induced Edema in Mice. 
o = Dexamethasone 
x = Chlorpromazine 
~ = Diphenhydramine 
0= Indomethacin 
.lf- = Aspirin 
~ = Phenylbutazone 
I 
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Figu:r:e 8. Log Dose-Response Curve for Cryogenine· and Three Str:uctural 
Components in Regard to the Suppression of Croton Oi!l-Induced 
Edema in Mice. 
~ = Indomethacin 
o = JB-1-0 
x = Cryogenine 
D = p-Hydroxycinnamic Acid 
... = Cinnamic Acid 
I 
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Figure 9. Log Dose-Response Curve for Cryogenine, Lythrine, JB'-1-0 
and Indomethacin in Regard to the Suppression of Cro1ton 
Oil-Induced Edema in Mice~ 
0 = Indomethacin 
11 = cryogenine 
x = Lythrine 
o = JB-1-0 
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Table VI. Comparison of Test Compounds to Indomethacin in Supr1ressing 
Croton Oil-Induced Ear ~dema in Mice i · 
! 
I 
Compound Potency (95% C.L.) Lambda ID50 (mg) IID50 (umoles) 
I 
I 
Indomethacin 1.0 -1 12.7 - 9.5xl0 
I 
Dexamethasone l7.80a -4 -4 - 2.7xl0 6.9xl0 
Chlorpromazine 33.7 (20.9-54.6) 0.36 -2 -2 2.2xl0 7.lxl0 
-2 I Diphenhydramine 14.7 (9.7-21.9) 0.30 5.3xl0 12.lxl0-2 
I 
3.lxl0:-l 
I -1 JB-1-0 2.8 (1.4-2.9) 0.25 8.4xl0 
Lythrine 2.0 (1.4-2.9) 0.27 4.lxl0 -1 9.4xl0 -1 
Cryogenine 1.6 (1.0-2.5) 0.33 5.5xl0 -1 
1
1.3 
Aspirin 0.8 (0.6-1.0) 0.23 1.2 :6.7 
p-Hydroxy-
cinnamic acid 0.6 (0.4-0.9) 0.30 1.4 I 8.8 
Phenylbutazone 0 . 4 ( 0 . 3- 0 . 6 ) 0.27 3.0 I 9. 7 
Cinnamic acid 0.1 (0.1-0.3) 0.38 
a A lambda value and 95% C. L. for the potency cannot: be calcul:a ted since 
thedose-response curves are not parallel. 
~Calculated from ID
50 
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52 
dose response slopes were not parallel; however the mean 
lambda value for the remaining assays was 0.30. 
' 
It was possible to document dose-response curves that 
would allow valid rn
50 
estimations for all compounds except 
cinnamic acid for which the responses did not reach 40 
percent inhibition -- a response considered as evidence 
of effectiveness. Kaplan, et al. (11) have shown this com-
pound to be ineffective orally against carrageenan-induced 
pedal edema and adjuvant-induced polyarthritis in rats. The 
dose-response curve of dexamethasone was significantly flatter 
than those of the other compounds. This finding and its very 
high potency would appear to place dexamethasone in a 
separate pharmacologic class from the other agents tested. 
Considering the relatively high molecular potencies obtained 
for chlorpromazine and diphenhydramine, the croton oil ear 
edema assay is not specific for anti-inflammatory compounds. 
This observation is further substantiated by the ability of 
ethacrynic acid, a potent diuretic, to be more active than 
indomethacin in this assay yet devoid of any activity in the 
carrageenan pedal edema assay (45). 
--------------- - ---- - - ------- ---- -----------·---- ---
DISCUSSION 
) 
Dr. James Quick of Northeastern University and the 
Sheehan Institute of Research provided this laboratory with 
the four synthetic quinolizidine compounds illustrated in 
Figure 1. Since these agents had not been screened pre-
viously for their anti-inflammatory capacity, it was im-
portant to establish whether any poss.essed significant ac-
tivity against carrageenan-induced pedal edema. 
The pathway to acute carrageenan-induced inflammation 
has been delineated by Vinegar, et al. (50) and involves a 
twelve-step process. Edema formation is dependent on the 
generation of a neutrophil chemotactic factor with a sub-
sequent neutrophil migration followed by the in situ genera-
tion of a vasoactive prostaglandin intermediate which in-
creases local capillary permeability. Vane, et al. (51, 52) 
demonstrated that the common non-steroidal anti-inflammatory 
drugs inhibit prostaglandin synthetase and, moreover, that 
a correlation exists between in vitro synthetase inhibition 
53 
~~--~---------~ -- --- -- ---~-- - --------------
54 
and in vitro anti-inflammatory activity. Subsequent investi-
gations (48) have implicated the highly-labile prostaglandin 
intermediates as inflammo.gens since their biological 
activity exceeds the potency of the prostaglandins. 
Of the four compounds evaluated, only JB-1-0 was ef-
fective at an oral dose of 100 mgjkg. The capacity of 
JB-1-0 to inhibit significantly the second stage of carra-
geenan-induced pedal edema is consistent with the activity 
of cryogenine and several clinically-effective anti-
inflammatory agents; however, second-stage inhibition fails 
to differentiate between peripheral and centrally-mediated 
activity. De Cato, et al. (19) found cryogenine's anti-
inflammatory capacity to be dependent on an intact pituitary-
adrenal axis, although not affected by the central sedation 
induced by phenobarbital. Therefore, while the sedation 
observed in the JB-1-0 treated animwls supports the drug's 
ability to penetrate the blood-brain barrier, the extent to 
which this involvement contributes to its anti-inflammatory 
activity remains to be determined. Since the molecular 
weights of the four synthetic quinolizidines are roughly 0.85 
times that of cryogenine, effectiveness at the 100 mgjkg dose 
was considered to be a realistic criterion to be met if fur-
ther testing was to be done. Thus, only JB-1-0 was selec-
t~d for additional screening. 
The croton oil-induced mouse ear edema assay is an 






the antiphlogistic potential of topically-applied drugs. 
The assay allows for concurrent assessment of systemic 
percutaneous absorption, using thymus involution as an in-
dex of adreno-cortical activity. Janoff, et al. (53) have 
demonstrated marked microvascular damage with associated 
functional changes after a single application of phorbol 
myristate acetate (the active principle in croton oil) to 
mouse ears .----Tlils-aam~Cge -t<f ~.l:fef vascula_r_ emiothe-li urn- is 
generally restricted to the venules and is accompanied by 
an increase in mast cell degranulation; however, these 
workers were unable to inhibit these acute inflammatory 
changes by systemic pretreatment with chlorpheniramine, 2-
BOL (2-bromolysergic acid diethylamide) dibenzyline, hydro-
cortisone or aspirin. These data suggest that while sys-
temic absorption of the drug substance following topical 
application is probable, the effect. of this absorption 
is minor and any significant anti-inflammatory acti~ity 
must be initiated by the compound at the site of applica-
tion. Therefore, the inhibition of mouse ear edema induced 
by croton oil reflects a compound's capacity to interact 
with local vascular and cellular events that contribute to 
the acute inflammatory response. 
Four of the reference compounds selected for the croton 
oil study are clinically useful anti-inflammatory agents. 
While their capacities to suppress the manifestations of 
acute and chronic inflammatory states run somewhat parallel, 
- ----------------------- --=========== 
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their potencies and mechanisms of action vary with consider-
able complexity (54). 
Dexamethasone, a synthetic steroid with high anti-
inflammatory and glucocorticoid activity, is the most potent 
and has been shown to (i) inhibit alterations in vascular 
tone and cap_illary permeability, ( ii) inhibit proliferation 
of capillaries and fibroblast and collagen deposition, (iii) 
stabilize lysosomal membranes, (iv) inhibit cellular meta-
bolism, (v) inhibit the generation of kinins, (vi) inhibit 
the responses of leukocytes and macrophages, (vii) inhibit 
chemotaxis, (viii) alter the immune response and (ix) in-
hibit arachidonic acid generation from phospholipids. The 
croton oil-induced mouse ear edema assay displays a high 
sensitivity for topically~applied steroids (46). In the 
present study, dexamethasone was found to be 1780 times 
more potent than indomethacin. This value is in agreement 
with the work of prior investigators (46, 47) and suggests 
that "high potency" is a restricted domain reserved for 
steroids and allows for a presumptive determination regard-
ing a test compound's corticoid-like activity. 
Indomethacin, phenylbutazone and aspirin represent a 
class of compounds collectively referred to as non-steroidal 
anti-inflammatory agents (NSAI) and while each compound is 
currently believed to exert its anti-inflammatory activity 
by interfering with arachidonic acid metabolism, each poss-




several of the events that mediate acute and chronic inflam-
matory responses. Indomethacin has been shown to (i) inhibit 
5-hydroxytryptophan decarboxylase, (ii) suppress kallikrein-
induced increases in permeability, (iii) uncouple oxidative 
phosphorylation, (iv) inhibit mucopolysaccharide biosynthesis, 
(v) inhibit ameboid motility of PMN leukocytes and (vi) re-
act with selected serum and tissue proteins. Aspirin and 
phenylbutazone both have the capacity to (i) uncouple oxi-
dative phosphorylation,. ( ii) stabilize lysosomal membranes, 
(iii) inhibit synthesis of mucopolysaccharides.and (iv) in-
hibit histamine release. However, aspirin also has been 
found to interact with kinin formation and suppress anti-
body production and antigen-antibody reactions. Furthermore, 
the ability of sodium salicylate to suppress clinically-
established inflammation· while being relatively inactive 
in inhibiting in vitro prostaglandin synthetase suggests 
that no single mechanism of action can adequately account 
for a drug's involvement with the dynamic inflammatory pro-
cess. 
The fact that cryogenine, lythrine and JB-1-0 all dis-
play similar dose-response profiles that closely parallel 
those of indomethacin, aspirin and phenylbutazone would sug-
gest that the lythraceae alkaloids do not possess significant 
corticoid-like activity when applied topically. However, 
this would not rule out the capacity of these agents to 
interact with the pituitary-adrenal axis upon systemic 
administration. 
rc=================~- -- -~ --
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Chlorpromazine has been shown to possess significant 
antiphlogistic activity in the carrageenan pedal edema assay 
(11). While this drug's diverse pharmacological profile 
suggests several potential mechanisms which may interact 
with the inflammatory response (55), it remains ineffective 
in the treatment of clinically-established inflammatory 
disorders. The present investigation determined chlorpro-
mazine to be 34 times more potent than indomethacin in 
inhibiting the acute inflammatory response induced by croton 
oil. This impressive potency for a nonsteroidal agent sug-
gests that these two agents may differ in mechanism(s) of 
action in this particular model of inflammation. While 
histamine plays a negligible role in the development of 
carrageenan-induced rat pedal edema (50), its involvement 
during the first two hours of croton oil-induced edema has 
been established (53). Chlorpromazine has antihistaminic 
capability (56), and the fact that diphenhydramine, a 
clinically-established antihistamine, was found to be 15 
times more potent than indomethacin in the present study 
indicates the relatively high activity of a histamine an+· 
tagon±st in this particular inflammatory model. The high 
potency of chlorpromazine, when compared to diphenhydramine, 
may be due to additional localized mechanisms which also 
contribute to chlorpromazine's antiphlogistic capacity. 
The documented antihistaminic pr0perties of crY,ogenine (13) 
may play a role in suppressing croton oil-induced mouse ear 
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edema; however, its capacity to inhibit carrageenan- and 
mycobacterium adjuvant-induced inflammations, where hista-
mine involvement is insignificant, suggests a true anti-
inflammatory potential. 
The test compounds evaluated in this study (cryogenine 
lythrine, JB-1-0, cinnamic acid and para-hydroxycinnamic 
acid) were selected with the intent of determining some of 
---------:--t-he --s-t-ruc-t-u-r-a-1--Peq-u-i-!!emen-t-s -vJhich- account- -for --cryogenine !_g __ -----
anti-inflammatory activity. Lythrine, the trans geometric 
isomer of cryogenine, was selected to assess any potential 
stereospecificity for molecular interactions with the hypo-
thetical "cryogenine receptor." The potencies of these 
two alkaloids were found to be virtually identical; thus, 
unlike indomethacin (57), no apparent stereospecific con-
formation is preferred. This hypothesis is further supported 
by the activity of JB-1-0, a racemic mixture, yet relatively 
equipotent to cryogenine and lythrine. Since cryogenine, 
lythrine and JB-1-0 all have the same dimethoxy substitution 
pattern on the phenyl ring, the importance of this region can 
not be fully evaluated; however, it is noteworthy that of the 
four synthetic compounds screened in the carrageenan pedal 
edema assay, JB-1-0 was the only one which displayed sig-
nificant activity. The other three compounds are substituted 
in the 3', 4', positions instead of the 4', 5', positions. 
The possibility that steric hinderance occurs when the phenyl 
ring is substituted in the 3' position deserves further evalua-
tion. 
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Since most of the clinically-effective anti-inflammatory 
drugs are acidic molecules, it seems plausible to suspect 
the cinnamic acid moeity of cryogenine and lythrine as the 
active center for anti-inflammatory activity. This idea is 
supported by the findings of Weibelhaus, et al. (24) and 
two brief reports (58, 59) describing the antiphlogistic 
properties of cinnamic acid. Kaplan, et al. (11) found cin-
- -- - - --- -
namic acid to be devoid of any significant anti-inflammatory 
activity against carrageenan-induced rat pedal edema. While 
the present study found cinnamic acid to be ineffective, its 
para-hydroxy analog did elicit a measurable anti-inflammatory 
response. This analog more closely resembles the acidic 
function found in the lythraceae alkaloids and this is note-
worthy, since Van Arman (48) contends that phenolic compounds 
inhibit inflammation by acting as radical scavengers, Their 
interaction with a highly reactive "hydroxy-radical" in-
creases the net turnover of arachidonic acid resulting in 
decreased local tissue levels of the highly reactive endoper-
oxides and the "hydroxy-radical"--both of which have been 
linked to the inflammatory process. While Weibelhaus, et al. 
( 24) imply tha't lythrin~' s para-hydroxycinnamic moei ty is 
essential for activity, the present study found JB-1-0 to 
be equipotent to the two parent compounds. 
Perhaps the most unique feature of the lythraceae alka-
loid's anti-inflammatory capacity resides in the fact that 
,•. 
they are nitrogenous bases. Whitehouse (60) proposed that 
~_, 
:i ,. 
---------- ----- -- -----------
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the acidic nature of standard non-steroidal anti-inflammatory 
drugs facilitates anionic binding to the lysyl E-amirro 
groups of certain enzyme systems normally engaged in ATP 
biosynthesis. Scherrer (61) has described a similar recep-
tor consisting of a large flat area, a trough to accommodate 
an out-of-plane group and a cationic site to accommodate 
acidic anions or unprotonated amines. While this model 
conforms to the molecular makeup of indomethacin, aspirin 
and phenylbutazone, it does not account for the anti-
inflammatory activity of cryogenine, lythrine and JB-1-0 
which would remain highly protonated at physiological con-
ditions. Therefore, while the present study serves to help 
delineate the active moeity of cryogenine and lythrine and 
documents their topical anti-inflammatory activity (systemic 
and topical activity were also determined for structurally 
related JB-1-0), the exact mechanisms which account for the 
antiphlogistic potential of these compounds still remain 
to be determined. 
Subsequent to the investigationsdiscussed here, a series 
of four homologs of JB-1-0 were submitted to this laboratory 
for investigation as a separate study. A·report of the 
results is included here as Appendix A. The discovery that 
SIR-92 exceeds the anti-inflammatory potency of JB-1-0 in-
dicates that these compounds do indeed represent a fertile 
area for structure-acti~ity research. 
62 
Recently, Lema et.al. (62) in a preliminary study, found 
cryogenine to inhibit the in vitro synthesis of prostaglandins, 
displaying a dose-response profile very similar to the 
clinically-established anti-inflammatories aspirin and 
phenylbutazone. Further investigation of cryogenine's 
effect on prostaglandin biosynthesis coupled with an evalua-
tion of the drug's ability to modulate cyclic nucleotide 
levels and alter neutrophil migration are indicated to deter-
mine whether cryogenine's unique chemical structure offers 
any equally unique pharmacological approach for countering 
the inflammatory process. 
]====================----- -----
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CONCLUSION 
Since prehistory, innumerable plant drug products have 
undergone long-term "clinical trials" due to their ubiquit-
ous employment as tribal medicinals and ritual drugs. While 
the reports of such use are subject to mythic distortion, 
they direct the pharmacologist to plants with active prin-
ciples whose a priori safety and efficacy warrant, at least, 
some scientific evaluation. The wide-spread use of Heimia 
salicifolia as an ethnobotanical among the Indians of 
Central and South America·suggests, if nothing more, a low 
order of toxicity in man. Since all the drugs currently 
available in the United States for the treatment of rheuma-
toid arthritis and related inflammatory conditions have 
undesirable side effects on chronic use, the lythraceae 
alkaloids may represent a potentially safe, new pharmacologic 
prototype with systemic and/or topical anti-inflammatory 
activity. 
Pre1iminary investigation of four synthetic phenyl-
63 
r=· ~~=--=· =-=~~=--=-~-~-~~=-=--=---~-~==---=--=---====-·-·· ·-- ·--·--
64 
quinolizidines established that one of these compounds, 
4-(2-bromo-4,5-dimethoxy phenyl) octahydro-2H-quino1izine-
2-one (JB-1-0), was capable of suppressing the inflammatory 
response induced by the sub-plantar injection of carrageenan 
in rats at an oral dose whi.ch is surely effective for cryo-
genine. 
The topical anti-inflammatory potencies of cryogenine · 
---------~ver-t~i-ne-)-anEl~l-y-t-hi'-i-ne-{both-isolated- from- Heimia salicifoliat -~ 
and JB-1-0 were determined using the method of Van Arman 
(47). When applied to the ears of female Swiss-Webster mice 
one hour after the application of 2 percent croton oil, 
potencies relative to indomethacin were, respectively: 
1.59 (1.01-2.50)--95% confidence-limits, 2.04 (1.43-2.92), 
and 2.82 (2.00-4.00). Two structural components of the 
natural alkaloids, para-hydroxycinnamic acid and cinnamic 
acid, were less potent than indomethacin: 0.62 (0.41-0.93) 
and 0.14 (0.01-0.03). Other reference compounds included: 
dexamethasone,· 1789 (837-3774,· estimated); chlorp~omazine, 
33.7 (20.9-54.6); diphenhydramine, 14.7 (9.7-21.9); aspirin, 
0.76 (0.55-1.04); and phenylbutazone, 0.39 (0.27-0.56). The 
mean lambda value for these assays was 0.30; this value ex-
cludes the dexamethasone-indomethacin assay since these two 
compounds have significantly different dose-response slopes. 
In 1971, Chang and Malone (16) suggested that chemical 
modification of cryogenine could result in a new class of 
potent, nonsteroidal, anti-inflammatory agents. In 1973, 
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Weibelhaus, et al. (24) reported the alteration of lythrine's 
anti-inflammatory and diuretic properties by chemical reduc-
tion of the cinnamic acid moeity to form decinine. The 
data in the present study suggest that the reactive com-
ponent for anti-inflammatory activity resides within the 
phenyl-quinolizidine portion of the lythraceae alkaloids 
______ r~1_h~_!' _tl:!l!_n_j:h~_Q:i_nn_a.l!ll-~-~C?-:i-Q_po_rtiQ_n and -tl:lat_ this a<;_t~y_i~y ____ _ 
is not stereospecific with respect to the quinolizidine 
ring fusion. Since bromide substitution of the phenyl ring 
yields a compound (JB-1-0)- with significant anti-inflarrunatory 
activity in two standard assays, further substitution of 
the phenyl-quinolizidine ring system may well provide even 
more potent anti-inflammatory agents. 
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APPENDIX A 
DATE: April 14, 1981 
TO: Dr. James Quick 
SISA Institute for Research 
- -- ----- ----7Cl3D-COi1Cor-d--AVeillie-
Cambridge, MA 02138 
Inc. 
RE: Report of Results of Anti-inflammatory Screen-
ing of Four Synthetic Compounds (SIR-85, SIR-
86, SIR-91, SIR-92) and Suitable Controls. 
(Synthetic compounds Mailed by Dr. Quick to 
Dr. Malone, October 17, 1980) 
REF: Notebook 25, pp. 229-236, 244-248. 
Experimental. Because of the very limited amounts of the 
synthetics made available, the anti-inflammatory activity 
was determined using the croton oil mouse ear edema assay 
of Tonelli et al. (46) as modified by Van Arman (47). This 
assay has been shown by Byrne and Malone (63) to yield 
positive results for lythraceae alkaloids and a chemically 
related compound previously submitted to this laboratory 
by Dr. Quick [4-(2-bromo-4, 5-dimethoxyphenyl)-octahydro-2H-
quinolizin-2-one]. 
Adult, healthy, female Swiss-Webster derived mice 
(17-20 g; Simonsen Laboratories, Gilroy CA) were housed in 
our facilities for at least one week prior to use and main-
tained on Purina Lab Chow and tap water ad libitum. One 
71 
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hour prior to experimentation, the mice were randomly placed 
in individual cages with wide-mesh screen floors to prevent 
coprophagy and provided with free access to food and tap 
water for the remainder of the experiment. Each mouse was 
anesthetized with ether USP and, upon loss of righting re-
flex, 0.1 ml of a mixture containing 2% croton oil, 73% 
ether, 20% pyridine, and 5% double-distilled water was ap-
plied in four aliquots using a 25-microliter Eppendorf 
pipette (two applications to the anterior and two to the 
posterior surfaces of each animal's right ear). 
One hour after the application of the croton oil-
containing vehicle, the i.ndividual test compounds were dis-
solved or suspended at concentrations containing the specific 
drug dose in 0.1 ml of a vehicle consisting of· 75% ether, 
20% pyridine and 5% double-distilled water. The mice were 
again anesthetized with eth~r USP and 0.1 ml. of drug-
containing solution/suspension applied to the right ear 
in the manner previously described. Drug-free vehicle was 
applied to the right ears of the control animals. 
Three hours after drug application, each mouse was 
sacrificed with ether USP and both the right and left ears 
excised at the base. A 8.0-mm circle of ear tissue was 
removed with a size #4 cork borer, using the outer margin 
of the ear as a landmark in order to avoid the extra hair 
and tissue associated with the base of the ear. Each sec-
tion was individually placed in marked spot-test plates 
73 
to insure proper identification and then weighed to the 
nearest tenth of a milligram using a Sartorius laboratory 
balance. 
The increase in weight induced by croton oil was found 
by subtracting the weight of the untreated left ear from 
that of the corresponding right ear. Drug effects (express-
ed as percent inhibition) were determined by subtracting 
the weight increase of treated individual ears from the 
mean weight increase of the control group and this dif-
ference (times 100) divided by the mean weight increase of 
the controls. , 
The ID50 values (the dose capable of reducing croton 
oil-induced edema by 50 percent) and the potency estimates 
relative to indomethacin as a standard were calculated math-
em~tically using regression methodology. Results are sum-
marized in Table VII. 
Test Compounds. The identity of the test compounds submitted 
are noted in Figure 10 along with their "code names 11 for 
this study. Also tested was JB-1-0, since that compound 
has been shown to be active using this technique (63). 
Results. We originally reported that JB-1-0 was active and 
2.82 times the potency of indomethacin (63). The present 
data indicate a potency of 2.67 times indomethacin, which 
figure is in very close agreement. All four of the SIR com-
pounds were active and all somewhat more potent than 
Figure 10. Structures, Code Identification, and 




SIR-85, very light canary yellow 
(250 mg., m.p. 84-85, sol. dilute 
acid, c16H21No2 , Batch 195.64 & 195.77) 
~Ne--~-------------
~~~ SIR-86, creamy white 
I 
~ acid, c16H01No2 , Batch 195.69 !i O
A (400 mg., m.p. 79-80, sol. dilute 
,. 195.72) .... 
SIR-91, creamy white 
(400 mg., m.p. 57.5-58.5,. sol. 
dilute acid, c18H25No3 , Batch 
B-208.46) 
SIR-92, white fine crystals 







, Batch A~208.46) 




Table VII. Anti-inflammatory Effects Against Croton Oil-Induce~i Ear Edema in Mice 
I 
!. 
Dose-Response D1se Reducing 
Mean Percent Slope, b !Edema 50% 
Inhibition (Correlation I ID5o• 
Compound MgjEar + 1 SEMa Coefficient, r) I mgjear Potency 
58.93 (0.68l)b 
I 
Indomethacin 0.25 39.0 + 8.5 !0.352b 1.00 
0.50 63.4 + 4.4 
1.00 74.5 + 2.9 
JB-1-0 0.25 62.2 + 6.4 38.52 (0.606)b :o.132b 2.67 
0.50 69.3 + 4.4 
1.00 85.4 + 2.2 
SIR-85 0.125 39.7 + 6.1 55.84 (o.709)b :0.196b 1. 80 
0.25 54.7 + 5.8 
0.50 73.2 + 2.8 
SIR-86 0.25 58.2 + 5.2 44.81 (0.525)c ! 0.164c 2.15 
0.50 62.8 + 9.3 
1.00 68.2 + 5.1 
SIR-91 0.125 47 .{) + 7. 6 41.21 (0.491)b io.163b 2.16 
0.25 54.1 + 8.4 
0.50 71.8 + 2.6 
SIR-92 0.25 76.5 + 3.5 9.24 (0.193)d J:o.107d ;.»-3. 29d 
0.50 72.2 + 3.8 
I 
1.00 82.1 + 5.8 
----~-~~~-~-~~~~~----~---,=----------, il 
Table VII. Continued 
aEight animals per test group. Inhibition expressed 
drug) group (N = 12) where mean edema formation was 
relative ito a control (non-
18.59 mg (S.E.M. = 1.86). 
bCalculated from regression equation where x = 
inhibition (arithmetic). 
log dose per ear 
I 
and y = percent 
COnly two doses (0.25 and 0.50 mg) were submitted to 
the response of the highest dose was clearly in the 
response) of the dose-response curve. 
I 
I 
regressi~n analysis, since 
I 
asymptotic section (active 
I 
I 
dAll three doses are in the upper asymptotic section (active ~~esponse) of the 
dose-response curve, so estimates of ID5o and potency were m:::_tde using graphical 
means. Lower doses would have been used on a subsequent day j, but initial testing 
had consumed the entire 25 mg sample. The graphical estimate presumes that SIR-
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indomethacin, with SIR-85 being the least potent of the series, 
SIR-86 and SIR-91 being essentially equipotent, and SIR-92 
being the most potent and at least 3.29 times the potency 
of indomethacin. The activity of SIR-92 was clearly under-
estimated and all doses produced what can be termed as 
"maximally effective" responses. Testing a range of lower 
doses was indicated, but the 25-mg sample had been completely 
----- ---- - ----------------
consumed by the initial trials. For a nonsteroidal compound, 
the activity of SIR-92 is quite impressive. 
